知镜 Cognispect · 医学文献与研究工作台

Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications.

Tachi K, Agyei-Nkansah A, Atiase Y, Forkuo B, Agyen-Frimpong VA.
BMJ open gastroenterology · 2026-07-02 · PMID 42392672

文献摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and type 2 diabetes mellitus (T2DM) are interconnected global epidemics that frequently coexist and mutually reinforce disease progression and adverse clinical outcomes. MASLD, the most prevalent chronic liver disease worldwide, is now recognised as a hepatic manifestation of systemic metabolic dysfunction. The coexistence of the triad markedly accelerates MASLD progression, heightens cardiometabolic risk and shifts mortality patterns towards cardiovascular disease, the leading cause of death in affected populations. However, most available data describe MASLD in association with either obesity or T2DM individually, while robust epidemiological or mechanistic evidence for their combined overlap remains scarce. This review synthesises current evidence on the epidemiological overlap and shared risk architecture linking MASLD, obesity and T2DM. We examine integrated pathophysiological and molecular mechanisms underpinning this triad, including insulin resistance, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, transcriptional and epigenetic dysregulation and gut-liver axis perturbations. We further discuss the clinical implications of this shared biology, emphasising integrated screening strategies and presenting an evidence-based algorithm for non-invasive identification of advanced hepatic fibrosis within the triad. We review evidence-based therapeutic approaches, including mechanism-based pharmacological therapies, and highlight their differential effects on weight, glycaemic control and liver disease severity. Emerging research priorities and future directions for integrated cardiometabolic care are also outlined. Collectively, the review underscores the need for integrated hepatic-cardiometabolic care to improve clinical outcomes across this metabolic triad.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。